UNITED STATES
                      SECURITIES AND EXCHANGE COMMISSION
                              WASHINGTON, D. C.
                                       
                                       
                                 FORM 10-QSB
                                       
                                       
                                       
              QUARTERLY REPORT UNDER SECTION 13 OR 15(D) OF THE
                       SECURITIES EXCHANGE ACT OF 1934
      
      
      
                           FOR THE QUARTER ENDED MARCH 31, 1999
                             COMMISSION FILE NUMBER: 0-24378
      
      
                            FIRST SCIENTIFIC, INC.
      EXACT NAME OF SMALL BUSINESS ISSUER AS SPECIFIED IN ITS CHARTER).
      
      
                  DELAWARE                         33-0611745        
	-------------------------------   -------------------------------
     (STATE OR OTHER JURISDICTION      (IRS EMPLOYER IDENTIFICATION NO.)
     OF INCORPORATION OR ORGANIZATION)
      
               1877 WEST 2800 SOUTH, SUITE 200, OGDEN, UTAH  84401
               ---------------------------------------------------
                    (ADDRESS OF PRINCIPAL EXECUTIVE OFFICES) 
                                       
   REGISTRANT'S TELEPHONE NUMBER, INCLUDING AREA CODE:    (801) 393-5781
                                       
                                       
      Indicate by check mark whether the registrant (1) has filed all
      reports required to be filed by Sections 13 or 15(d) of the Securities
      Exchange Act of 1934 during the preceding 12 months (or for shorter
      period that the registrant was required to file such reports), and (2)
      has been subject to such filing requirements for the past 90 days.
      
      YES     X        NO       
      
      
      These were 20,169,770 shares of common stock, $.001 par value,
      outstanding as of May 11, 1999.
      
      
      
      
                                  FIRST SCIENTIFIC, INC.
                                       FORM 10-QSB
      
      
                               QUARTER ENDED MARCH 31, 1999
      
                                    TABLE OF CONTENTS
      
                              PART I - FINANCIAL INFORMATION
    
      
      Item 1.   Financial Statements
      
      
      Condensed Consolidated Balance Sheets (Unaudited) -
       March 31, 1999 and December 31, 1998. . . . . . . . . . . . . . . . . 3
         
      Condensed Consolidated Statements of Operations (Unaudited) 
       for the Three Months Ended March 31, 1999 and 1998
       and for the Cumulative Period from April 30,
       1990 (Date of Inception) through March 31, 1999 . . . . . . . . . . . 4
              
      Condensed Consolidated Statements of Cash Flows (Unaudited) 
       for the Three Months Ended March 31, 1999 and 1998. . . . . . . . . . 5
              
      
      Notes to the Condensed Consolidated Financial Statements 
       (Unaudited) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6
         
      Item 2.  Management's Discussion and Analysis and Plan of Operation. . 8
      
      
                               PART II - OTHER INFORMATION
      
      Item 1.  Legal Proceedings . . . . . . . . . . . . . . . . . . . . . . 12
        
      Signatures . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13
      
      
      
      
                              PART I   FINANCIAL INFORMATION
      
      ITEM 1.   Financial Statements
      
                                  FIRST SCIENTIFIC, INC.
                             (A DEVELOPMENT STAGE ENTERPRISE)
                          CONDENSED CONSOLIDATED BALANCE SHEETS
                                       (UNAUDITED)
      
                                                     March 31,   December 31,
                                                       1999          1998
                                                    -----------  -----------
                                          ASSETS
      
      CURRENT ASSETS
       Cash                                          $  964,607  $ 1,286,299
       Investment in securities available-for-sale      194,286      194,784
       Trade receivables                                     75          614 
       Inventory                                         51,909       26,619
       Prepaid expenses                                  21,087       29,356
                                                     ----------  -----------
        TOTAL CURRENT ASSETS                          1,231,964    1,537,672
       
      PROPERTY AND EQUIPMENT                            124,686      95,378
       Less: accumulated depreciation                    (7,826)     (2,982)
                                                     ----------   ---------
        NET PROPERTY AND EQUIPMENT                      116,860      92,396
      
      PURCHASED TECHNOLOGY, NET                          86,250     108,750 
      
      INVESTMENT IN EQUITY SECURITIES, AT COST               -       50,000
                                                     ----------  ----------
      TOTAL ASSETS                                   $1,435,074  $1,788,818
                                                     ==========  ==========
      
                           LIABILITIES AND STOCKHOLDERS' EQUITY
      
      CURRENT LIABILITIES
       Accounts payable                              $   59,350   $  54,334
       Customer deposits                                 33,750      33,750
       Accrued liabilities                               29,357      75,979
       Capital lease obligation - current portion         3,323       2,070
       Related party notes payable                       22,694      22,693
                                                     ----------   ---------
        TOTAL CURRENT LIABILITIES                       148,474     188,826
                                                     ----------   ---------
      LONG-TERM CAPITAL LEASE OBLIGATION                  6,981       4,784
                                                     ----------   ---------
      STOCKHOLDERS' EQUITY
       Preferred stock 1,000,000 shares authorized, 
        no shares outstanding                                -           -
       Common stock $.001 par value, 50,000,000
        shares authorized; issued and outstanding:
        20,169,770 shares at March 31, 1999 and
        December 31,1998                                 20,170      20,170
       Additional paid-in capital                     6,429,114   6,429,114
       Unearned compensation                            (68,572)    (84,056)
       Accumulated other comprehensive loss             (57,775)     (7,275) 
       Deficit accumulated during the
        development stage                            (5,043,318) (4,762,745)
                                                     ----------  ----------
        TOTAL STOCKHOLDERS' EQUITY                    1,279,619   1,595,208
                                                     ----------  ----------
      TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY     $1,435,074  $1,788,818
                                                     ==========  ==========
      
   The accompanying notes are an integral part of these financial statements.


                    FIRST SCIENTIFIC, INC. AND SUBSIDIARY
                       (A DEVELOPMENT STAGE ENTERPRISE)
                    CONSOLIDATED STATEMENTS OF OPERATIONS
                                 (UNAUDITED)
<TABLE>
<CAPTION>
                                                                     Cumulative From
                                                                      April 30, 1990
                                             For the Three Months   (Date of Inception)
                                                 Ended March 31,          Through
                                            -------------------------    March 31,
                                                1999         1998          1999
                                            -----------   -----------   -----------
<S>                                        <C>           <C>           <C>
SALES                                       $       370   $       271   $   236,366
COST OF SALES                                       247           108       154,900
                                            -----------   -----------   -----------
GROSS PROFIT                                        123           163        81,466
                                            -----------   -----------   -----------
OPERATING EXPENSES
   General and administrative expense           285,415        14,797     1,122,747
   Research and development expense               6,262         4,570     3,995,812
                                            -----------   -----------   -----------
     TOTAL OPERATING EXPENSES                   291,677        19,367     5,118,559
                                                                        
LOSS FROM OPERATIONS                           (291,554)      (19,204)   (5,037,093)

OTHER INCOME AND (EXPENSE)
   Interest income                               12,146            -         26,828
   Interest expense                              (1,165)       (8,022)      (94,934)
                                            -----------   -----------   -----------
LOSS BEFORE INCOME TAXES                       (280,573)      (27,226)   (5,105,199)

BENEFIT FROM INCOME TAXES                            -             -         61,881
                                            -----------   -----------   -----------
NET LOSS                                    $  (280,573)  $   (27,226)  $(5,043,318)
                                            ===========   ===========   ===========

BASIC AND DILUTED LOSS PER COMMON SHARE     $     (0.01)  $     (0.00)  $     (0.48)
                                            ===========   ===========   ===========
WEIGHTED AVERAGE NUMBER OF  SHARES USED 
 IN PER-SHARE CALCULATION                    20,169,770    10,467,581    10,584,687
                                            ===========   ===========   ===========
<FN>
 The accompanying notes are an integral part of these financial statements.
</FN>
</TABLE>


                             FIRST SCIENTIFIC, INC.
                        (A DEVELOPMENT STAGE ENTERPRISE)
                CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
                                  (UNAUDITED)

<TABLE>
<CAPTION>
                                                                     Cumulative From
                                                                      April 30, 1990
                                             For the Three Months   (Date of Inception)
                                                 Ended March 31,          Through
                                            -------------------------    March 31,
                                                1999         1998          1999
                                            -----------   -----------   -----------
<S>                                        <C>           <C>           <C>
 CASH FLOWS FROM OPERATING ACTIVITIES
    Net loss                                $  (280,573)  $   (27,226)  $(5,043,318)
    Adjustments to reconcile net loss to
     net cash used in operating  activities:
       Depreciation and amortization             27,344            -         56,576
       Common stock issued for services              -             -         74,355
       Common stock issued for purchased 
        research and development                     -             -      3,766,440
       Compensation from stock options
        granted                                  15,484            -        105,622
       Deferred tax benefit                          -             -        (61,881)
       Changes in operating assets and 
        liabilities:
          Accounts receivable                       539         8,425           (75)
          Inventory                             (25,290)           -        (51,909)
          Prepaid expenses                        8,269            -        (21,087)
          Customer deposits                          -             -         33,750
          Accounts payable                        5,016         1,005        59,350
          Accrued liabilities                   (46,622)        5,480       161,789
          Deferred compensation                      -          1,225            -
                                            -----------   -----------   -----------
      NET CASH USED IN OPERATING ACTIVITIES    (295,833)      (11,091)     (920,388)
 
 CASH FLOWS FROM INVESTING ACTIVITIES
    Cash paid for equipment                     (29,309)           -       (116,970)
    Cash received from sale of securities
     available-for-sale                              -             -        302,847
                                            -----------   -----------   -----------
      NET CASH PROVIDED BY (USED IN) 
       INVESTING ACTIVITIES                     (29,309)           -        185,877
                                            -----------   -----------   -----------
 
 CASH FLOWS FROM FINANCING ACTIVITIES
    Proceeds from borrowing                       4,336            -        260,311
    Principal payments on notes payable              -         (2,382)     (155,975)
    Proceeds from loans from stockholders            -          6,197       158,934
    Principal payments on loans from 
     stockholder                                     -             -        (63,807)
    Principal payment under capital lease 
     obligation                                    (886)           -         (1,748)
    Proceeds from issuance of common stock           -             -      1,501,403
                                            -----------   -----------   -----------
     NET CASH PROVIDED BY FINANCING 
      ACTIVITIES                                  3,450         3,815     1,699,118
                                            -----------   -----------   -----------
 NET INCREASE (DECREASE) IN CASH               (321,692)       (7,276)      964,607
 
 Cash and Cash Equivalents at Beginning 
  of Period                                   1,286,299         7,938            -
                                            -----------   -----------   -----------
 CASH AND CASH EQUIVALENTS AT END 
  OF PERIOD                                 $   964,607   $       662   $   964,607
                                            ===========   ===========   ===========
<FN>
 The accompanying notes are an integral part of these financial statements.
</FN>
</TABLE>
 
                        FIRST SCIENTIFIC, INC.
         NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
                              (UNAUDITED)
 
 NOTE 1-- SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
 
 INTERIM CONDENSED FINANCIAL STATEMENTS The accompanying condensed
 consolidated financial statements are unaudited. In the opinion of
 management, all necessary adjustments (which include only normal
 recurring adjustments) have been made to present fairly the
 financial position, results of operations and cash flows for the
 periods presented. Certain information and note disclosures
 normally included in financial statements prepared in accordance
 with generally accepted accounting principles have been condensed
 or omitted. It is suggested that these condensed consolidated
 financial statements be read in conjunction with the First
 Scientific financial statements and notes thereto included in the
 Form 10-KSB dated December 31, 1998. The results of operations for
 the three month period ended March 31, 1999 are not necessarily
 indicative of the operating results to be expected for the full year.
 
 PRINCIPLES OF CONSOLIDATION - The accompanying condensed 
 consolidated financial statements include the accounts and
 transactions of First Scientific, Inc. and its wholly-owned
 subsidiary, First Scientific Corporation, since the date of its
 acquisition. Intercompany accounts and transactions have been
 eliminated in consolidation. The consolidated entities are
 collectively referred to herein as "First Scientific."
  
 NOTE 2--COMPREHENSIVE LOSS
 
 Other comprehensive income of First Scientific consists of
 unrealized losses on investment in securities available-for-sale
 and is as follows:
 
<TABLE>
<CAPTION>
                                                                     Cumulative From
                                                                      April 30, 1990
                                        For the Three Months  (Date of Inception)
                                           Ended March 31,          Through
                                      -------------------------    March 31,
                                         1999         1998          1999
                                      -----------   -----------   -----------
<S>                                  <C>           <C>           <C>
 NET LOSS                             $ (280,573)   $   (27,226)  $(5,043,318)
 
 OTHER COMPREHENSIVE LOSS
  Unrealized loss on investment 
   in securities available-
   for-sale                              (50,500)            -        (57,775)
                                      ----------   ------------   -----------
 COMPREHENSIVE LOSS                   $ (331,073)  $    (27,226)  $(5,101,093)
                                      ==========   ============   ===========

 NOTE 3--SUPPLEMENTAL CASH FLOW INFORMATION
 
 Interest paid during the three months ended March 31, 1999 and
 1998, was $598 and $2,542, respectively, and $93,639 for the
 period from April 30, 1990 (date of inception) through March 31, 
 1999.
 
 NOTE 4--COMMITMENTS AND CONTINGENCIES
 
 CAPITAL LEASE - During the first quarter of 1999 First Scientific
 entered into a capital lease agreement for computer equipment. 
 The lease agreement is for a 3-year term requiring monthly
 payments of $177 and a present value of $4,336 at inception of the 
 lease.
 
 UNASSERTED CLAIM - On January 5, 1999 First Scientific was advised
 of a claim against it allegedly arising out of an Agreement in
 Principle made in 1991 (the "1991 Agreement") by Linco Industries,
 Inc. (a predecessor to First Scientific Inc.'s wholly-owned
 subsidiary). The 1991 Agreement purported to promise shares of
 Linco common stock to an individual if certain conditions were met
 in representing Linco to potential customers.  No legal proceeding
 has been filed with respect to this claim, nor has First
 Scientific made any settlement offer in an attempt to resolve the
 matter. First Scientific's management maintains that the 1991
 Agreement is no longer valid because the conditions in the 1991
 Agreement were not met in a reasonable time and because of the 
 failure of other material terms.  Additionally, an indemnification
 agreement in favor of First Scientific by the former founding
 Linco shareholders requires the latter to satisfy any obligations
 Linco incurred prior to the reorganization.  Consequently, First
 Scientific would require that any eventual settlement or award
 resulting from the 1991 Agreement be satisfied entirely by the
 founding shareholders of Linco.  The Linco founders have made a
 settlement offer to the Claimant and have assured First Scientific
 that they will defend this matter in the event any legal
 proceedings should be filed against First Scientific.


 ITEM 2.  MANAGEMENTS'S DISCUSSION AND ANALYSIS AND PLAN OF
 OPERATIONS.
  
  The following discussion and analysis provides information which
 management believes is relevant to an assessment and understanding
 of First Scientific's consolidated results of operations and
 financial condition.  The discussion should be read in conjunction
 with the unaudited condensed consolidated financial statements, as
 of March 31, 1999, together with the annual financial statements
 as of December 31,1998.  Whenever in this discussion the term
 "First Scientific" is used, it should be understood to refer to
 First Scientific, Inc. ("First Scientific") and its wholly owned
 subsidiary on a consolidated basis, except where the context
 clearly indicates otherwise. 
                                          
 Plan of Operations
 ------------------
  First Scientific is a development stage company which, since
 inception, has incurred losses from operations. As of March 31,
 1999, the cumulative net losses of First Scientific since
 inception total $5,043,318 of which $3,766,440 is attributable to
 acquired research and development, as described in First
 Scientific's annual report on Form 10-KSB dated December 31, 1998.
 First Scientific is engaged primarily in the development of
 chemical formulations that appear to have worldwide sales
 application.  First Scientific has chosen to market its products
 initially through private label relationships with companies that
 are major distributors in the over-the-counter, medical,
 healthcare and multi-level arenas.   Development of the First
 Scientific's own brands, which will be sold through regional
 distributors, especially in medical markets, will be pursued on a
 case-by-case basis as profitable opportunities are identified.  
 
  First Scientific has developed two unique formulations; the first
 is a moisturizing antibacterial sanitizing formulation that
 removes 99.99% of bacteria from the skin without the harsh effects
 of alcohol or iodine (this product can be delivered in wipes,
 spray, gel-lotion and lotion-soap form) and the second, a topical
 rash prevention and treatment formulation that cleanses and
 moisturizes the skin for treatment against skin rashes caused by
 incontinence and other skin rashes (in wipe form). 
 
  The worldwide market for products similar to those being
 developed by First Scientific has grown significantly in recent
 years and is projected to continue growing at a substantial rate. 
 Regarding First Scientific's antibacterial formulation, the growth
 in demand of this product line is due to the increase in bacteria
 related disease, sickness and death from methicillin-resistant and
 other bacteria, the demands of government and healthcare
 agencies/providers to create healthier treatment environments and
 the insistence of the public in general for healthier living and
 working conditions.  Increasing market growth for diaper and other
 rash formulations is primarily a function of the tremendous growth
 rate of the  incontinent geriatric population, as baby boomers
 grow older, and the product's application for the infant market. 
 Management believes the markets for products First Scientific is
 developing  will continue to expand and that the potential of
 First Scientific to become a significant participant  in such
 markets is a reasonable expectation, however the realization of
 revenues from these efforts is not assured
 
  First Scientific currently outsources manufacturing of its
 products. First Scientific has developed relationships with
 manufacturers who have U.S. Food and Drug Administration
 ("F.D.A.") compliant facilities and years of experience
 manufacturing according to F.D.A. standards. These companies are
 in the business of manufacturing for various customers who require
 F.D.A. compliant facilities for their products.  First Scientific
 is able to produce a concentrate of its antibacterial formulation
 at its own facility, or at nearby contract facilities, under
 F.D.A. protocols. The concentrate can then be shipped to its
 contract manufacturers for production runs according  to  customer
 specifications.  This procedure helps protect the trade secret
 status of this proprietary formulation. However, First Scientific
 does not use this procedure in the production of its Dimethicone
 based rash prevention and treatment formulation, because currently
 the Company cannot economically mix concentrate for this product. 
 Strict confidentiality agreements are in place with the
 manufacturer to protect the trade secret status of this product
 formulation. Future dealings with major private labelers may lead
 to deviation from these procedures. Such deviations, that may
 include the preparation of concentrate at a contract manufacturer
 who are privy to First Scientific's formulations, may be justified
 based on the economic value of such relationships. 
 
  The cash requirements of First Scientific for the foreseeable
 future will vary based upon a number of factors including, but not
 limited to, continuing research and development levels, market
 development, facilities enhancement, additional personnel, travel
 and other expenses related to projected growth. With the new
 business First Scientific is now negotiating, management believes
 that existing funds and funds generated from anticipated sales
 will be sufficient to meet the obligations of First Scientific
 over the next nine to twelve months. However, in light of
 management's cash consumption projections for the remaining nine
 months of its fiscal year, if anticipated sales do not materialize
 in a timely manner at projected volumes, First Scientific would
 likely need a bank line of credit and/or additional equity funding
 to meet its working capital needs by the first quarter of 2000.
 There is no  assurance that any funding would be available or
 that, if available, the terms of such funding will be favorable to
 First Scientific.
 
  A new source of revenue has developed for First Scientific.  A
 large multinational drug company recently engaged First
 Scientific, on a fee for service basis, to perform testing
 procedures that fulfill FDA regulatory compliance requirements
 relating to potential product sales to this customer.  Initial
 responses from this customer are favorable regarding First
 Scientific's testing procedures and operating protocols.  The
 prospects for ongoing testing work with this customer appear
 likely. This experience has allowed First Scientific to develop
 standard operating procedures that satisfy not only this
 customer's needs, but that should withstand the most critical
 evaluations and requirements of future customers, therefore,
 providing new revenue.                   
 
  Product research and development is an ongoing process at First
 Scientific.  Existing products are  continually being refined to
 meet the needs of markets being developed. Potential customers
 also present product specifications from time to time which are
 different from those of First Scientific's existing products. 
 These circumstances cause additional research and development to
 be performed in order to meet the specifications required.  First
 Scientific likewise researches new products that fall within the
 scope of its currently defined market place and new market places
 that appear to have future economic potential.                  
  
  Given First Scientific's current mode of operations of
 outsourcing its manufacturing, existing plant and equipment are
 projected to be sufficient to meet most of its growth needs.
 However, should First Scientific decide, or be required, to
 perform expanded testing for its clients and/or should it move to
 in-house manufacturing, additional capital would be required to
 fund the establishment of such activities. 
 
  First Scientific now employs seven individuals in management,
 administrative, and technical positions. As First Scientific
 continues to grow, additional personnel will need to be added to
 enable it to meet projections. Specifically, a Vice President of
 Sales and Marketing will be added to the Company's management team
 during the second quarter. Projections also call for adding a lab
 testing/quality control manager, another lab assistant and an
 executive secretary before years end. These projected hires will
 represent a fifty-seven percent increase in First Scientific's 
 workforce.
 
  
 Management's Discussion and Analysis of Financial Condition and
 Results of Operations
  
 Financial Position
 ------------------
  First Scientific had $964,607 in cash as of March 31, 1999. This
 represents a decrease of  $321,692 from December 31, 1998. Working
 capital, as of March 31,1999, decreased to $1,083,490 compared to
 working capital of $1,398,846 at December 31, 1998. 
 
 Results of Operations
 ---------------------      
  Sales were nominal during the three months ended March 31, 1999
 and 1998 which reflects that the Company has yet to obtain any
 significant customers for its products.
       
  Prior to December 1998 Company revenues were generated from
 sporadic sales of a Linseed oil based soap product and a rash
 prevention product created for a distributor who sells this
 product under private labels to an over-the-counter customer.
 First Scientific has decided to discontinue the sale of these
 products, but does expect minimal revenue as existing inventory is
 liquidated.  In June 1998, First Scientific entered into a private
 label supply agreement with a multinational distributer of medical
 and healthcare products.  This agreement is for individual
 antibacterial wipes that  the customer plans to export.  As of
 March 31,1999; however, the manufacturing of this product has not
 been completed  because of delays caused by internal business
 restructuring at the private labeler and production scheduling by
 First Scientific's contract manufacturer. It is contemplated that
 this production will be done in the second quarter of 1999. 
 Serious negotiations continue to progress with other potential
 domestic  private label customers and an international customer. 
 First Scientific is disappointed that negotiations with a major
 division of a Fortune 100 company has not formally concluded;
 nevertheless, substantive progress has been made with them. 
 Management believes a  significant contract will be signed with
 this company in the second quarter of 1999.  Should this or other
 potential opportunities not materialize, First Scientific's
 ability to sustain operations beyond the end of 1999, without
 additional debt or equity financing, would be questionable.  
 
  Private label agreements, such as those discussed above, create
 certain risks for First Scientific, including (i) reliance for
 sales of products on other parties, and therefore reliance on the
 other parties' marketing ability, marketing plans and
 credit-worthiness; (ii) if First Scientific's products are
 marketed under other parties' labels, goodwill associated with use
 of the products may inure to the benefit of the other parties
 rather than First Scientific; (iii) First Scientific may have only
 limited protection from changes in manufacturing costs and raw
 materials costs; and (iv) if First Scientific is reliant on other
 parties for all or substantially all of its sales, First
 Scientific may be limited in its ability to negotiate with such
 other parties upon any renewals of their agreements.  It is the
 belief of management that these risks are mitigated by initial
 market demands, the apparent uniqueness of its formulations, 
 large existing and expanding markets  for its products and  the
 caliber of customers with which it is  currently negotiating. 
 However, First Scientific recognizes that, in the short run, it
 will be dependent on a few large customers where the bulk of its
 sales will be generated.  Until a broader base of customers is
 established, the loss of one such customer could have a serious
 negative impact on the operating viability of First Scientific. 
 
  First Scientific uses as many as twenty specific chemical and
 botanical ingredients to formulate its products.  Supplies of 
 ingredients for First Scientific's formulations continues to
 remain readily available from multiple sources, in most cases.
 First Scientific continues to maintain very good relationships
 with its suppliers and does not anticipate problems that would
 cause significant interruption, delay or availability of such 
 ingredients.
 
  General and administrative expenses were $ 285,415 for the three
 months ended March 31, 1999, compared with $ 14,797 from the prior
 year's period. The increase in expenditures between the 1999 and
 1998 periods was due to the continued transition of First
 Scientific  from a one-man product development entity, with
 minimal sales during the first quarter of 1998, to an adequately
 staffed operation capable of administrating  anticipated growth.  
 Executive office space that First Scientific moved  into during
 1998 should meet growth needs for the foreseeable future.
 Remodeling of the space it had previously occupied was completed
 during the current quarter. This space will be used for research,
 testing, mixing and  warehousing.
 
  Research and development expenses were $6,262 for the three 
 months ended March 31, 1999 compared with $4,570  for  the
 comparable periods from the prior year.  The increase in
 expenditures between the 1999 and 1998 periods resulted from the
 continued refinement of First Scientific's formulations and the
 development of new product variations to meet customer request
 Management expects an increase in research and development
 expenses for future periods, as First Scientific expands its
 product offerings. 
           
 Liquidity and Capital Resources
 -------------------------------      
  Historically, First Scientific has financed its operations
 principally through  loans, private placements of equity
 securities and sporadic product sales; however, minimal capital
 was generated during the three months ended March 31, 1999 from
 these sources. First Scientific used net cash in operating
 activities of $ 295,833 during the three months ended March 31,
 1999. As of March 31, 1999, First Scientific's liabilities 
 totaled $ 155,455. First Scientific had working capital as of the
 end of the current quarter, March 31,1999, of $ 1,083,490.  
 
 Year 2000
 ---------
  First Scientific uses computers principally for scientific
 modeling and calculation, product/market research  and
 administrative functions such as communications, word processing,
 accounting and management and financial reporting. First
 Scientific's computer system was purchased September, 1998. The
 software utilized by First Scientific is generally standard "off
 the shelf" software, typically available from a number of vendors.
 While First Scientific believes it has taken all appropriate steps
 to assure year 2000 compliance, it is dependent substantially on
 vendor compliance. Should vendor assurances that First
 Scientific's systems are 2000 compliant be incorrect, management
 believes systems failures would not have a material adverse impact
 on its operations.
 
  In addition to its own computer systems, in connection with its
 business activities, First Scientific interacts with suppliers,
 customers, creditors and financial service organizations
 domestically and globally who use computer systems. It is
 impossible for First Scientific to monitor all such systems, and
 there can be no assurance that the failure of such systems would
 not have a material adverse impact on First Scientific's business
 and operations. First Scientific is currently evaluating what
 contingency plans it may adopt in the event First Scientific or
 parties with whom First Scientific does  business experience year
 2000 problems.
 
 Forward-Looking Statements
 --------------------------
  When used in this Form 10-Q and in other filings by First
 Scientific with the SEC, in First Scientific's press releases or
 other public or stockholder communications, or in oral statements
 made with the approval of an authorized executive officer of First
 Scientific, the words or phrases "would be," "will allow,"
 "intends to," "will likely result," "are expected to," "will
 continue," "is anticipated," "estimate," "project," or similar
 expressions are intended to identify "forward-looking statements"
 within the meaning of the Private Securities Litigation Reform Act
 of 1995.
 
  First Scientific cautions readers not to place undue reliance on
 any forward-looking statements, which speak only as of the date
 made, are based on certain assumptions and expectations which may
 or may not be valid or actually occur, and which involve various
 risks and uncertainties, including but not limited to risk of
 product demand,  market acceptance, economic conditions,
 competitive products and pricing, difficulties in product
 development, commercialization, and technology, and other risks.
 In addition, sales and other revenues may not commence and/or
 continue as anticipated due to delays or otherwise. As a result,
 First Scientific's actual results for future periods could differ
 materially from those anticipated or projected.
 
  Unless otherwise required by applicable law, First Scientific
 does not undertake, and specifically disclaims any obligation, to
 update any forward-looking statements to reflect occurrences,
 developments, unanticipated events or circumstances after the date
 of such statement.
 
 
                     PART II   OTHER INFORMATION
 
 ITEM 1.  LEGAL PROCEEDINGS.
 
  First Scientific is not involved in, nor has it been involved 
 in, any legal proceedings.  On January 5, 1999 First Scientific
 was advised of a claim against it allegedly arising out of an
 Agreement in Principle made in 1991 (the "1991 Agreement") by
 Linco Industries, Inc. (a predecessor to First Scientific Inc.'s
 wholly-owned subsidiary). The 1991 Agreement purported to promise
 shares of Linco (now First Scientific) common stock to an
 individual if certain conditions were met in representing Linco to
 potential customers.  No legal proceeding has been filed with
 respect to this claim, nor has First Scientific made any
 settlement offer in an attempt to resolve the matter.  First
 Scientific's management maintains that the 1991 Agreement is no
 longer valid because the conditions in the 1991 Agreement were not
 met in a reasonable time and because of the  failure of other
 material terms.  Additionally, an indemnification agreement in
 favor of First Scientific by the former founding Linco
 shareholders requires the latter to satisfy any obligations Linco
 incurred prior to the reorganization. Consequently, First
 Scientific would require that any eventual settlement or award
 resulting from the 1991 Agreement be satisfied entirely by the
 founding shareholders of Linco. The Linco founders have made a
 settlement offer to the Claimant and have assured First Scientific
 that they will defend this matter in the event any legal
 proceedings should be filed against First Scientific.


                              SIGNATURES
 
       
 Pursuant to the requirements of the Securities and Exchange Act of
 1934, the Registrant has duly caused this report to be signed on
 its behalf by the undersigned thereunto duly authorized.


                              REGISTRANT
       
                        FIRST SCIENTIFIC, INC.
                              Registrant
       
       
 DATED:         May 11, 1999        By:  /s/ Douglas R. Warren
                                    ------------------------------
                                      Douglas R. Warren, President
       
 
 DATED:       May 11, 1999          By: /s/ Gordon M. Davis
                                    -------------------------------
                                    Gordon M. Davis, Vice President
                                    Administration/CFO (Principal 
                                    Financial and Accounting Officer)


</TABLE>